Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

Gustafsson, Emil; Litström, Emma; Berterö, Carina; Drott, Jenny

doi:10.1007/s00520-015-2838-y

Cited by 11 publications

(17 citation statements)

References 38 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Oxaliplatin‐associated neurotoxicity questionnaire (OANQ), developed by Leonard et al consists of three parts with 19 total questions—focused on upper and lower extremities and the oral/facial area. The OANQ demonstrates good reliability, with good test‐retest reliability, and internal consistency . The scale for chemotherapy‐induced long‐term neurotoxicity (SCIN) was specifically developed to address neurological toxicities in cisplatin‐treated testicular cancer survivors and accordingly contains neuropathy, Raynaud's phenomenon and ototoxicity subscales …”

Section: Resultsmentioning

confidence: 99%

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Park

Alberti

Kolb

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major toxicity of cancer treatment, leading to dose reduction and premature treatment cessation, potentially affecting patient function, and quality of life. The development of accurate and sensitive assessment tools for CIPN is essential to enable clinical monitoring during treatment, follow-up of long-term outcomes and measurement of toxicity in clinical trials.This review examines CIPN clinical assessment scales incorporating clinician-based, composite, and patient-reported outcomes (PROs), providing a systematic review of their properties and an updated critical analysis of recommendations on current evidence for their use. This systematic review of CIPN assessment tools identified 50 papers containing 41 assessment tools, across 4 categories (common toxicity criteria; composite neurological scale; PROs; pain scale). The majority of these tools were PROs, underscoring the importance of patient-based assessment of symptoms.While there has been considerable work in the field over the past 10 years, this review highlights significant gaps, including a lack of evaluation of responsiveness and problematic neuropathic pain evaluation. There remains a need for consensus on the best available tool and the need to modify existing instruments to improve utility. K E Y W O R D S assessment, chemotherapy, CIPN, neuropathy, neurotoxicity, outcome measures 1 | INTRODUCTION Chemotherapy-induced peripheral neurotoxicity (CIPN) is a prominent adverse event of cancer treatment, leading to dose reduction and premature treatment cessation, potentially affecting patient function and quality of life. The development of accurate and sensitive assessment tools for CIPN is essential to enable clinical monitoring during treatment, follow-up of long-term outcomes and measurement of toxicity in clinical trials. As with all treatment toxicities, a balanced approach between patient report, objective examination and clinician discretion is warranted. It is likely that tailored assessment strategies will be required to facilitate appropriate assessment in different contexts ranging from routine clinical screening tools to comprehensive multimodal assessments and outcome measures in clinical trials. Assessment tools which do not require specialised equipment are most accessible for routine clinical use. While common toxicity criteria (CTC) are the most commonly utilised assessment tools for a range of cancer treatment toxicities including CIPN, validated patient-reported outcome (PRO) measures provide sensitive assessment of neuropathy symptoms and significance for the patient. Composite neurological assessments containing a combination of symptom report and neurological examination findings provide another method of CIPN evaluation. Given the importance of selecting appropriate outcome measures, including in drug development and for regulatory approval, review of the properties of CIPN assessment tools is warranted.From this search, a total of 50 papers meeting inclusion criteria wer...

show abstract

Section: Resultsmentioning

confidence: 99%

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Park

Alberti

Kolb

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

show abstract

“…These patients were in outpatient hospital care, so it seemed to be important to enhance the follow-up of this patient group. In this study we identified the patient's neurotoxic side effects using OANQ [17,30], via a self-report mobile phone system; an appropriate way for professionals to follow symptom progression.…”

Section: Discussionmentioning

confidence: 99%

The trajectory of neurotoxic side effects’ impact on daily life: a qualitative study

Drott

Starkhammar

Kjellgren

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Purpose To explore the experiences of oxaliplatin-induced neurotoxic side effects among patients with colorectal cancer (CRC), and how these side effects influenced their daily lives over time.Methods To assess neurotoxic side effects, ten patients were repeatedly interviewed. The patients were recruited from two hospitals in south of Sweden, had stage II-III CRC, and had been treated with adjuvant oxaliplatin postoperatively, from November 2013 to October 2015. They had received FOLFOX and XELOX, with a mean total dose of 791 mg oxaliplatin. After completed chemotherapy, at 3, 6 and 12 months into the post-treatment phase, 25 interviews were conducted and thematic analysis was used according to Braun and Clarke.Results Oxaliplatin-induced neurotoxicity affects patients in several ways in the long term. Four themes were identified: Expectation of cure, Dubiety, Normalization and Learn to live with neurotoxity. The findings of this study describe the trajectory of neurotoxicity and its impact on these patients' life situation. The findings confirmed that neurotoxicity is multi-faceted and that the experience of it changes over time. ConclusionThe desire to survive stimulates adaptations and strategies to manage daily life, and patients learn to live with the neurotoxic side effects. This study provides evidence that these patients need individual attention and support during the trajectory of neurotoxic side effects. Current care provision is inadequate due to lack of knowledge of the ways in which neurotoxicity impacts the patient's daily life. This study provides insights that could be used to develop more person-centered care.

show abstract

“…Intraclass Correlation (ICC) for symptom items and effect on daily activities items showed overall excellent reproducibility. The weighted kappa for symptom items and daily activities-items showed overall feasibility 15 .…”

Section: Questionnairementioning

confidence: 92%

“…Patients with cancer discharged from hospital have positive experiences of reporting side effects using mobilephone technology and it is useful throughout the cancer-care trajectory 17 . Assessment of OXA-NTS was performed in real time, using the Swedish version of the OANQ in a mobile phonebased system (21st Century Mobile AB, http:// www.cqmobil.se) 15,17 , at baseline before the initial OXA treatment cycle (C), the day before (d-1) and two days (d2) after each OXA treatment. The evaluation time-points were selected to capture NTS appearance; the day before (d-1) since there should be no NTS and two days (d2) after since the acute NTS should had disappeared.…”

Section: Real-time Assessmentmentioning

confidence: 99%

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

et al. 2018

View full text Add to dashboard Cite

Background: Oxaliplatin (OXA) is frequently used in the treatment of patients with colorectal cancer (CRC) and OXA-induced neurotoxic side effects is common. Real time patient-reported neurotoxic side effects and impact on the patient's daily activities, are sparse in existing studies. Objective: This study aimed to identify and assess patient-reported OXA-induced neurotoxic side effects and their impact on the patient's daily activities, during and after chemotherapy. Methods: In a multicentre prospective longitudinal study, 46 chemo naïve patients with CRC treated with postoperative adjuvant OXA-based chemotherapy were monitored during treatment and at 3-, 6-, 9-and 12-month follow-ups. Patients were recruited from September 2013 to June 2016. In total, 370 OANQ (Oxaliplatin-Associated Neurotoxicity Questionnaire) responses were available for analysis. A mobile phone-based system was used to receive real time assessments. Results: All patients reported neurotoxic side effects and impact on daily activities during treatment. The side effects changed in character and body location over time, and had an impact on the daily activities. Conclusions: The high prevalence of OXA-induced neurotoxic side effects significantly interfered with the patients' daily activities. We found significant differences between baseline data and follow-up time points for neurotoxicity, and the patients had not returned to baseline after one year.

show abstract

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

Cited by 11 publications

References 38 publications

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity

The trajectory of neurotoxic side effects’ impact on daily life: a qualitative study

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

Contact Info

Product

Resources

About